Lu sur : https://www.ncbi.nlm.nih.gov/pubmed/31354544
Traduction disponible directement en cliquant en bas à droite de ce message sur l'expression Traduire en
Front Psychiatry. 2019 Jul 9;10:481. doi: 10.3389/fpsyt.2019.00481. eCollection 2019.
Risk of Depressive Disorders Following Myasthenia Gravis: A Nationwide Population-Based Retrospective Cohort Study.
Chu HT1, Tseng CC1, Liang CS1,2, Yeh TC3, Hu LY4,5, Yang AC5,6,7, Tsai SJ4,5,6, Shen CC5,8.
The chronic autoimmune disease myasthenia gravis (MG) is characterized by fluctuating muscle weakness, which can lead to a large amount of stress in the patient.
The current investigation plans to assess the risk of depressive disorders in MG patients.
A retrospective cohort study of patients ageing 20 years and older and also newly diagnosed with MG between January 1, 2000, and December 31, 2008, was conducted from the National Health Insurance Research Database (NHIRD) in Taiwan.
Observations of all 349 MG patients and 1,396 control individuals were made until a diagnosis of a depressive disorder by a psychiatrist, until death, or until December 31, 2013.
A range of comorbidities were found, such as coronary artery disease, hypertension, diabetes mellitus, and dyslipidemia, with cerebrovascular disease being reported more frequently in MG patients in comparison with control subjects.
After adjustment of patients' sex, age, urbanization, comorbidities, and monthly income, results indicated that MG individuals are 1.94 times more at risk (95% confidence interval [CI], 1.15-3.27, P = 0.014) of developing depressive disorders than are controls.
This showed an increased risk in the development of depressive disorders in people with MG. Thus, depressive symptoms in MG patients should be regularly assessed.
Article intégral, traduit en français, disponible pour nos donateurs